Merck’s Keytruda may be the most talked about drug facing loss of exclusivity but it’s far from the only one, as several of ...

BioBond Continues to Grow Its IP Portfolio to Commercialize Sustainable Adhesives and Coating Solutions LAFAYETTE, INDIANA / ...

BioBond Continues to Grow Its IP Portfolio to Commercialize Sustainable Adhesives and Coating Solutions LAFAYETTE, INDIANA / ...

NEW YORK: McKinsey & Co is beefing up its ethics department after a series of high-profile controversies, including helping Purdue Pharma LP “turbocharge” opioid sales. The management ...

McKinsey & Company Inc., a management consulting firm, recently agreed to pay $650 million to resolve a civil and criminal investigation into consulting work performed by the firm with opioids ...

A federal judge extended a pause protecting the Sackler family, owners of Purdue Pharma LP, from opioid lawsuits to give the OxyContin maker, states and victims representatives time to finalize a new ...

In the latest twist in its efforts to wrap up years of high-profile opioid litigation, the billionaire family behind the now-bankrupt Purdue Pharma, the Sacklers, has come back from last year’s ...

A bipartisan coalition of states has reached a $7.4 billion settlement in principle with members of the Sackler family and their former company Purdue Pharma over their role in the opioid crisis.

Bankrupt Purdue Pharma LP and its owners have agreed to over $7 billion settlement to resolve lawsuits over OxyContin's role in the opioid epidemic. The deal follows the U.S. Supreme Court’s ...

The Sacklers and Purdue Pharma boosted their settlement contribution to $7.4 billion after the U.S. Supreme Court overturned a prior settlement in June 2024. If approved, the new plan would end ...